291 related articles for article (PubMed ID: 23807360)
1. Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled Phase I studies.
Li RC; Li YP; Mo ZJ; Luo D; Huang T; Kong JL; Wang LH; Song NS; Liu A; Zhang H; Liao X; Karkada N; Han HH
Hum Vaccin Immunother; 2013 Aug; 9(8):1638-42. PubMed ID: 23807360
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial.
Cunliffe NA; Witte D; Ngwira BM; Todd S; Bostock NJ; Turner AM; Chimpeni P; Victor JC; Steele AD; Bouckenooghe A; Neuzil KM
Vaccine; 2012 Apr; 30 Suppl 1(0 1):A36-43. PubMed ID: 22520135
[TBL] [Abstract][Full Text] [Related]
3. Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China.
Li RC; Huang T; Li Y; Luo D; Tao J; Fu B; Si G; Nong Y; Mo Z; Liao X; Luan I; Tang H; Rathi N; Karkada N; Han HH
Hum Vaccin Immunother; 2014; 10(1):11-8. PubMed ID: 24013441
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants.
Li RC; Huang T; Li Y; Wang LH; Tao J; Fu B; Si G; Nong Y; Mo Z; Liao X; Luan I; Tang H; Rathi N; Karkada N; Han HH
Hum Vaccin Immunother; 2016 Mar; 12(3):785-93. PubMed ID: 27149266
[TBL] [Abstract][Full Text] [Related]
5. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study.
Omenaca F; Sarlangue J; Szenborn L; Nogueira M; Suryakiran PV; Smolenov IV; Han HH;
Pediatr Infect Dis J; 2012 May; 31(5):487-93. PubMed ID: 22228231
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity, reactogenicity and safety of a human rotavirus vaccine (RIX4414) in Korean infants: a randomized, double-blind, placebo-controlled, phase IV study.
Kim JS; Bae CW; Lee KY; Park MS; Choi YY; Kim KN; Kim JD; Park WS; Sin JB; Kim EA; Lee SG; Kim CS; Cha SH; Hong YJ; Shin SM; Shim GH; Choi KM; Yang JW; Liu A; Suryakiran PV; Han HH
Hum Vaccin Immunother; 2012 Jun; 8(6):806-12. PubMed ID: 22699440
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants.
Vesikari T; Karvonen A; Bouckenooghe A; Suryakiran PV; Smolenov I; Han HH
Vaccine; 2011 Mar; 29(11):2079-84. PubMed ID: 21238572
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants.
Steele AD; Reynders J; Scholtz F; Bos P; de Beer MC; Tumbo J; Van der Merwe CF; Delem A; De Vos B
J Infect Dis; 2010 Sep; 202 Suppl():S93-100. PubMed ID: 20684724
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.
Phua KB; Quak SH; Lee BW; Emmanuel SC; Goh P; Han HH; De Vos B; Bock HL
J Infect Dis; 2005 Sep; 192 Suppl 1():S6-S16. PubMed ID: 16088807
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants.
Salinas B; Pérez Schael I; Linhares AC; Ruiz Palacios GM; Guerrero ML; Yarzábal JP; Cervantes Y; Costa Clemens S; Damaso S; Hardt K; De Vos B
Pediatr Infect Dis J; 2005 Sep; 24(9):807-16. PubMed ID: 16148848
[TBL] [Abstract][Full Text] [Related]
11. Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh.
Zaman K; Yunus M; El Arifeen S; Azim T; Faruque AS; Huq E; Hossain I; Luby SP; Victor JC; Dallas MJ; Lewis KD; Rivers SB; Steele AD; Neuzil KM; Ciarlet M; Sack DA
Vaccine; 2012 Apr; 30 Suppl 1():A94-100. PubMed ID: 22520143
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial.
Lau YL; Nelson EA; Poon KH; Chan PK; Chiu S; Sung R; Leung CW; Ng D; Ma YM; Chan D; Lee TL; Tang J; Kwan YW; Ip P; Ho M; Fung LW; Tang H; Suryakiran PV; Han HH; Bock H;
Vaccine; 2013 Apr; 31(18):2253-9. PubMed ID: 23499605
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of pentavalent rotavirus vaccine in a randomized, double-blind, placebo-controlled study in healthy elderly subjects.
Lawrence J; He S; Martin J; Schödel F; Ciarlet M; Murray AV
Hum Vaccin Immunother; 2014; 10(8):2247-54. PubMed ID: 25424929
[TBL] [Abstract][Full Text] [Related]
14. The human rotavirus vaccine Rotarix™ in infants: an integrated analysis of safety and reactogenicity.
Buyse H; Vinals C; Karkada N; Han HH
Hum Vaccin Immunother; 2014; 10(1):19-24. PubMed ID: 24047799
[TBL] [Abstract][Full Text] [Related]
15. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.
Laserson KF; Nyakundi D; Feikin DR; Nyambane G; Cook E; Oyieko J; Ojwando J; Rivers SB; Ciarlet M; Neuzil KM; Breiman RF
Vaccine; 2012 Apr; 30 Suppl 1():A61-70. PubMed ID: 22520138
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial.
Iwata S; Nakata S; Ukae S; Koizumi Y; Morita Y; Kuroki H; Tanaka Y; Shizuya T; Schödel F; Brown ML; Lawrence J
Hum Vaccin Immunother; 2013 Aug; 9(8):1626-33. PubMed ID: 23732903
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants.
Narang A; Bose A; Pandit AN; Dutta P; Kang G; Bhattacharya SK; Datta SK; Suryakiran PV; Delem A; Han HH; Bock HL
Hum Vaccin; 2009 Jun; 5(6):414-9. PubMed ID: 19276664
[TBL] [Abstract][Full Text] [Related]
18. Safety, Reactogenicity, and Immunogenicity of Human Rotavirus Vaccine RIX4414 in Human Immunodeficiency Virus-positive Infants in South Africa.
Steele AD; Madhi SA; Louw CE; Bos P; Tumbo JM; Werner CM; Bicer C; De Vos B; Delem A; Han HH
Pediatr Infect Dis J; 2011 Feb; 30(2):125-30. PubMed ID: 20842070
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of the oral pentavalent rotavirus vaccine in Mali.
Sow SO; Tapia M; Haidara FC; Ciarlet M; Diallo F; Kodio M; Doumbia M; Dembélé RD; Traoré O; Onwuchekwa UU; Lewis KD; Victor JC; Steele AD; Neuzil KM; Kotloff KL; Levine MM
Vaccine; 2012 Apr; 30 Suppl 1():A71-8. PubMed ID: 22520140
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, Immunogenicity and Safety of a Human Rotavirus Vaccine RIX4414 in Singaporean Infants.
Phua KB; Lim FS; Quak SH; Lee BW; Teoh YL; Suryakiran PV; Han HH; Bock HL
Ann Acad Med Singap; 2016 Feb; 45(2):44-50. PubMed ID: 27125345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
